How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009–2013 [PDF]
, 2015 core +1 more source
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective? [PDF]
BioDrugsShin G, Han H, Choi G, Lee D, Bae S.
europepmc +1 more source
Optimizing the Approval Pathway for Biosimilars to Treat Psoriasis and Psoriatic Arthritis [PDF]
, 2012 Sheila Rittenberg, Bethany Wofford
openalex +1 more source
Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral Infections. [PDF]
PharmaceuticsHalawa M +5 more
europepmc +1 more source
Infliximab Biosimilar Utilization in a Large Pediatric Learning Health System. [PDF]
Children (Basel)Maltz RM, Saeed SA, Adler J.
europepmc +1 more source
Insulin Glargine Biosimilar Prescribing and Cost Trends in the United Kingdom's Primary Care from 2020 to 2024. [PDF]
Pharmacy (Basel)Alsaif M, Blumer Z.
europepmc +1 more source
Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013 [PDF]
, 2013 Antônio da Silva +8 more
openalex +1 more source
Perceptions and Preferences for Defining Biosimilar Products in Prescription Drug Promotion. [PDF]
J Am Board Fam MedJohnson M +4 more
europepmc +1 more source
Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars? [PDF]
, 2013 Howard Lee
openalex +1 more source
Switching from Adalimumab Reference Product to and Among Adalimumab Biosimilars Outside the USA: Insights for US Clinicians. [PDF]
BioDrugsTesser JRP, Charabaty A, Hebert AA.
europepmc +1 more source